United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

12:13pm EDT
Change (% chg)

$-0.42 (-1.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

UK's CMA could accept undertakings on Acadia's Priory Group deal
7:09am EDT 

UK's CMA : To look at Acadia's undertakings offer in relation to acquisition of Priory Group No 1 Ltd in detail . Considers that undertaking offered, or a modified version of it, might be accepted .Now has until 23 September to decide whether to accept undertaking, with possibility to extend this timeframe to 18 november.  Full Article

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:05pm EST 

ACADIA Pharmaceuticals Inc:t intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering.There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.ACADIA intends to grant the underwriters a 30-day option to purchase an additional $45,000,000 of shares of its common stock.  Full Article

ACADIA Pharmaceuticals Inc Appoints Steve Davis as Chief Executive Officer
Thursday, 3 Sep 2015 07:01am EDT 

ACADIA Pharmaceuticals Inc:Board of Directors has appointed Steve Davis as President and Chief Executive Officer.Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015.Davis has also been appointed to the ACADIA Board of Directors.  Full Article

ACADIA Pharmaceuticals submits new drug application for NUPLAZID for the Treatment of Parkinson's Disease Psychosis
Thursday, 3 Sep 2015 07:00am EDT 

ACADIA Pharmaceuticals Inc:Announces it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease.  Full Article

ACADIA Pharmaceuticals Inc announces change in Chief Executive Officer
Wednesday, 11 Mar 2015 04:02pm EDT 

ACADIA Pharmaceuticals Inc:Says Uli Hacksell has retired as ACADIA's Chief Executive Officer and as member of Board of Directors, effective today.Says Steve Davis, Executive Vice President, Chief Financial Officer and Chief Business Officer of ACADIA, has been appointed as Interim Chief Executive Officer.Says Hacksell will remain as special advisor to company during this transition period.ACADIA's Board of Directors plans to initiate search for permanent Chief Executive Officer.  Full Article

ACADIA Pharmaceuticals Inc updates planned timing of NUPLAZIDTM NDA Submission
Wednesday, 11 Mar 2015 04:01pm EDT 

ACADIA Pharmaceuticals Inc:Provided an update on planned timing of its NUPLAZID(pimavanserin) New Drug Application (NDA) submission.Plans to submit its NUPLAZID NDA for treatment of Parkinson's disease psychosis in the second half of 2015.Says company had previously planned to submit NDA in Q1 of 2015.Decision to move back planned submission is based on additional time required to complete preparation of systems to support commercial manufacturing and supply and, in turn, to support the U.S. Food and Drug Administration's (FDA) review of NUPLAZID.Change in submission timing is not result of any change to NUPLAZID's clinical or safety profile, nor is it a result of any interaction with or request for information from FDA.  Full Article

ACADIA Pharmaceuticals Inc presents Caregiver Burden Data
Monday, 8 Dec 2014 09:00am EST 

ACADIA Pharmaceuticals Inc:Says the presentation of caregiver burden data from its Phase III program with NUPLAZID (pimavanserin) for Parkinson's disease psychosis (PDP) at 10th Annual International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders held from Dec. 5-7 in Nice, France.Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.  Full Article

ACADIA Pharmaceuticals Inc receives FDA breakthrough therapy designation for NUPLAZID (Pimavanserin) for Parkinson's Disease Psychosis
Tuesday, 2 Sep 2014 09:00am EDT 

ACADIA Pharmaceuticals Inc:Announced that U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID (pimavanserin) for treatment of Parkinson's disease psychosis.Says NUPLAZID is selective serotonin inverse agonist and, if approved, will establish new and distinctly different pharmacological approach to treating psychosis.NUPLAZID has completed pivotal Phase III trial in Parkinson's disease psychosis, which FDA has agreed can serve as basis, together with supportive data from other studies, for a New Drug Application.ACADIA plans to submit NUPLAZID NDA to FDA near end of this year.  Full Article

BRIEF-Acadia's Nuplazid available for treatment of hallucinations, delusions associated with Parkinson's

* Nuplazid (pimavanserin) now available for treatment of hallucinations and delusions associated with Parkinson's disease psychosis Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)